Abbrea Capital’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | $5.36M | Sell |
31,251
-1,211
| -4% | -$201K | 0.71% | 35 |
|
|
2024
Q1 | $5.91M | Buy |
32,462
+235
| +0.7% | +$40.5K | 0.78% | 32 |
|
|
2023
Q4 | $4.99M | Sell |
32,227
-305
| -0.9% | -$44.5K | 0.72% | 35 |
|
|
2023
Q3 | $4.85M | Hold |
32,532
| – | – | 0.77% | 33 |
|
|
2023
Q2 | $4.38M | Buy |
32,532
+6
| +0% | +$880 | 0.67% | 35 |
|
|
2023
Q1 | $5.18M | Buy |
32,526
+4
| +0% | +$612 | 0.88% | 28 |
|
|
2022
Q4 | $5.26M | Buy |
32,522
+160
| +0.5% | +$24.5K | 0.95% | 27 |
|
|
2022
Q3 | $4.34M | Sell |
32,362
-423
| -1% | -$60.7K | 0.82% | 27 |
|
|
2022
Q2 | $5.02M | Sell |
32,785
-455
| -1% | -$69.5K | 0.84% | 27 |
|
|
2022
Q1 | $5.39M | Buy |
33,240
+265
| +0.8% | +$38.5K | 0.75% | 30 |
|
|
2021
Q4 | $4.46M | Buy |
32,975
+290
| +0.9% | +$34.3K | 0.6% | 41 |
|
|
2021
Q3 | $3.53M | Buy |
32,685
+360
| +1% | +$41.1K | 0.53% | 46 |
|
|
2021
Q2 | $3.64M | Buy |
32,325
+1,357
| +4% | +$153K | 0.55% | 46 |
|
|
2021
Q1 | $3.35M | Buy |
30,968
+516
| +2% | +$55.2K | 0.55% | 49 |
|
|
2020
Q4 | $3.26M | Buy |
30,452
+1,184
| +4% | +$114K | 0.58% | 45 |
|
|
2020
Q3 | $2.56M | Sell |
29,268
-500
| -2% | -$47.1K | 0.54% | 47 |
|
|
2020
Q2 | $2.92M | Buy |
29,768
+604
| +2% | +$53.2K | 0.67% | 39 |
|
|
2020
Q1 | $2.22M | Sell |
29,164
-280
| -1% | -$23.9K | 0.59% | 47 |
|
|
2019
Q4 | $2.61M | Sell |
29,444
-850
| -3% | -$70.6K | 0.55% | 46 |
|
|
2019
Q3 | $2.29M | Buy |
30,294
+2,760
| +10% | +$189K | 0.53% | 53 |
|
|
2019
Q2 | $2M | Sell |
27,534
-1,545
| -5% | -$121K | 0.49% | 55 |
|
|
2019
Q1 | $2.34M | Buy |
29,079
+390
| +1% | +$31.9K | 0.67% | 42 |
|
|
2018
Q4 | $2.65M | Sell |
28,689
-179
| -0.6% | -$15.7K | 0.87% | 38 |
|
|
2018
Q3 | $2.73M | Sell |
28,868
-140
| -0.5% | -$13.3K | 0.8% | 36 |
|
|
2018
Q2 | $2.69M | Buy |
29,008
+25
| +0.1% | +$2.44K | 0.84% | 37 |
|
|
2018
Q1 | $2.74M | Buy |
28,983
+648
| +2% | +$71.2K | 0.89% | 36 |
|
|
2017
Q4 | $2.74M | Sell |
28,335
-550
| -2% | -$51.8K | 0.93% | 35 |
|
|
2017
Q3 | $2.57M | Buy |
28,885
+150
| +0.5% | +$11.4K | 0.95% | 31 |
|
|
2017
Q2 | $2.08M | Buy |
28,735
+800
| +3% | +$53.8K | 0.83% | 40 |
|
|
2017
Q1 | $1.82M | Buy |
27,935
+1,365
| +5% | +$85.8K | 0.74% | 44 |
|
|
2016
Q4 | $1.66M | Buy |
+26,570
| New | +$1.62M | 0.78% | 45 |
|
Other funds holding ABBV
Abbrea Capital's ABBV Position: Q2 2024 in Review
Abbrea Capital reduced its AbbVie (ABBV) stake by 3.7% in Q2 2024, selling an estimated $201K and leaving 31,251 shares worth $5.36M. The position accounts for 0.71% of the portfolio, ranked #35.
Abbrea Capital first reported a position in ABBV in Q4 2016 and has held it in 31 quarters since. The position peaked at $5.91M in Q1 2024. 3,365 funds tracked by Wall St. Rank hold ABBV as of Q2 2024.
- Abbrea Capital held 31,251 shares of AbbVie worth $5.36M as of Q2 2024.
- Abbrea Capital sold 1,211 AbbVie shares in Q2 2024, an estimated $201K.
- AbbVie made up 0.71% of Abbrea Capital's portfolio in Q2 2024, its #35 holding.
- Abbrea Capital first reported a position in AbbVie in Q4 2016 and has held it in 31 quarters since.
- Abbrea Capital's AbbVie position peaked at $5.91M in Q1 2024.
- 3,365 funds tracked by Wall St. Rank held AbbVie as of Q2 2024.
Based on Abbrea Capital's 13F filing for Q2 2024, filed 8 Aug 2024.